Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University

Slides:



Advertisements
Similar presentations
 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Advertisements

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.
The Gamlen Tablet Press (GTP) Michael Gamlen Gamlen Tableting Ltd.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Methods of tablet manufacturing
Asthma  Most common chronic illness of childhood, affecting approximately 10% children.  Available preventive therapies for persistent asthma include.
Determine impurity level in relevant batches1
A Pharmaceutical Study on Felodipine “Enhanced Dissolution Characteristics of Felodipine” Ahmed Abd-El Bary, Mohamed M. Nafady,Mahmoud E. Nasr Department.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
1 Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July , 2008 Classification of Orally Disintegrating Tablets Frank O. Holcombe,
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Quality control Lecture 1.
Novel Multifunctional Excipients by Co-processing with Mg-Silicate Dr. Faisal Al-Akayleh Faculty of Pharmacy, Petra University.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
Liquisolid drug delivery system
Solid dosage forms Tablets
Suad Y. Alkarib 1 Dina Elraih 2 Waddah F. Nour 3.
GRANULATION DR. MOHAMMAD KHALID ANWER Assistant Professor 2/25/20161 COLLEGE OF PHARMACY, PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY.
Tablet Granulation. Introduction  Granulation is the process in which primary powder particles are made to adhere to form larger, multi particle entities.
Quality control Lecture 1.
Milling Is the reduction in the size mass by conversion of the large solid unit mass into smaller one by mechanical process. This needs energy.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
Physical Testing 1.Solutions 2.Disperse systems 3.Aerosols 4.Powders 5.Tablets 6.Sustained release products 7.Coated tablets 8.Hard & soft shell capsules.
Physico-chemical Control of Dosage Forms
Bayero University, Nigeria
- Pharmaceutical Equivalence Study
Introduction What is a Biowaiver?
ASSESSMENT OF THE IMPACT OF HUMIDITY ON STABILITY OF APOTRIAVIR TABLETS AND ITS IMPLICATION IN BETTER TASTE RELEASE TRACPlus 2010 KIGALI, November 11,
Solid dosage forms Tablets
Capsules, Tablets, and Powders
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
Gastrointestinal Absorption: Role of the Dosage Form
Biopharmaceutics of modified release drug products
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
Evaluation of tablet Lab 5.
WHO Technical Report Series, No. 953, 2009
Evaluation of tablet Lab 5.
TIMERx Oral Controlled-Release Drug Delivery System
Biopharmaceutic Considerations in Drug Product Design
IPSA (Industrial Problem Solving Ability )
Group members: Firdaus | Sofia | Nurainiza | Hafizah
Quality control Lecture 1.
Milling Lab-6-.
FARHANA AMIRAH NADIA AMIR
Quality Control Requirement
J.Preethi*, P. Madhu, K. Arshad Ahmed Khan.
Lab -7- Capsules.
The Biopharmaceutical Classification System (BCS)
Tablet Dosage Form Lab 1.
LAB.2 Tablet Production Methods
Lab 3 Industrial pharmacy
Mixing and Homogenization Lab (1) Shahen S. Mohammed MSc pharmaceutics
Selected Bioavailability and Pharmacokinetic Calculations
Lab -7- Capsules.
Chapter 6 Systems of Measurement in Veterinary Pharmacology
Micrometrics. It is the science and technology of small particles. Knowledge and control of the size and the size range of particles are of significant.
Quality by Design.
Aram I. Ibrahim University of sulaimani College of pharmacy
Pediatric Formulation Development - A quality perspective
Tablets Lecturer: dr. Asmaa abdelaziz Mohamed Faculty of pharamcay
POWDER AND GRANULES FADHILAH FAIROZA FATIN HUSNA
Quality control Lecture 1.
Evaluation of tablet Lab 5.
RingCap Technology Mrs. Maria Saifee Associate Professor,
University of sulaimani
Milling Lab-6-.
Tablets.
Presentation transcript:

Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University FORMULATION OF LEVOFLOXACIN AS ORODISPERSIBLE TABLETS USING A READY-MADE BLEND OF EXCIPIENTS COMPARED WITH CLASSIC FORMULATION STRATEGIES ISRAA H. AL-ANI,Ph.D Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University Jordan

INTRODUCTION Orodispersible tablets (ODTs) are defined as tablets that disperse or disintegrate in short time (upto 2minutes) in the mouth prior to being swallowed, which results in the rapid dissolution and absorption of the active pharmaceutical ingredients contained in these tablets, providing a rapid onset of action.

ODTs also provide specific advantages to pediatric and geriatric patient populations, which can sometimes experience difficulties in swallowing conventional tablets and capsules .

A variety of different processes have been developed for the production of ODTs, including freeze drying and molding, as well as several other more conventional methods, including dry and wet granulation processes and direct compression. The key challenges associated with the formulation of good ODTs include fast disintegration times, reasonably sized tablets, low moisture sensitivity and taste .

What are ready made excipients? The International Pharmaceutical Excipients Council (IPEC) defines excipients as "Substances, other than the API in finished dosage form, which have been appropriately evaluated for safety and are included in a drug delivery system to either aid the processing or to aid manufacture, protect, support, enhance stability, bioavailability or patient acceptability, assist in product identification, or enhance any other attributes of the overall safety and effectiveness of the drug delivery system during storage or use" .

Co-processing of excipients could lead to the formation of excipients with superior properties compared to the simple physical mixtures of their components. The main aim of co-processing is to obtain a product with added value related to the ratio of its functionality/price.

Development of co-processed directly compressible adjuvant starts with the selection of the excipients to be combined, their targeted proportion and the selection of preparation method to get optimized product with desired physico-chemical parameters, and it ends with minimizing avoidance with batch-to-batch variations. An excipient of reasonable price has to be combined with the optimal amount of a functional material in order to obtain an integrated product, with superior functionality to the simple mixture of components.

This synergistic effect should improve the quality of the tablet equally in all aspects ranging from hardness to dissolution and/or stability. Most important characteristics are the binding and blending properties of the co-processed excipients, which must be better than those of a physical mixture of the starting materials. Cost is another factor to be considered in the selection of co-processed product.

Major limitation of co-processed excipient mixture is that the ratio of the excipients in a mixture is fixed and in developing a new formulation, a fixed ratio of the excipients may not be an optimum choice for the API and the dose per tablet under development . Co-processed adjuvant lacks the official acceptance in pharmacopoeia. For this reason, a combination filler-binder will not be accepted by the pharmaceutical industry until it exhibits significant advantages in the tablet compaction when compared to the physical mixtures of the excipients.

Aim of the work The aim of this study was to compare the physical characteristics and dissolution properties of ODTs prepared using conventional methods with those prepared using a ready-made mixture of excipients (PROSOLV® ODT). These comparison experiments were conducted using levofloxacin as a model active pharmaceutical ingredient.

Experimental Part Levofloxacin: method of analysis and calibration curve (ICH guideline). Formulation of ODT. - preparation of the powder blends (weighing and mixing-using Cubic-mixer) Six formulas were prepared each contained 250 mg Levof. F1-F5 used physical mixture of Mannitol, disintegrants, Avicel, aspartam talc and Mg stearate. And F6 used the ready-made blend.

The target weight was 500 mg The target weight was 500 mg. Small scale of 500 tablets was prepared, then scaling up was achieved. - Evaluation of powder blend (particle size distribution, bulk density , tapped density, flowability and angle of repose and percentage comprisibility) Note: all tests followed USP requirements.

Table (1): The prepared formulas Ingredients F1 F2 F3 F4 F5 F6 Levofloxacin 250 CCS 25 35 SSG CP Aspartam 5 Talc 8 Mannitol 209 199 149 Avicel® 50 ® Mg Stearate 3 Total (mg) 500

Experimental Part “Particle size distribution (PSD) of a powder, or granular material, or particles dispersed in fluid, is a list of values or a mathematical function that defines the relative amounts of particles present, sorted according to size.” Samples were taken randomly from different levels of the vessel and were analyzed by laser diffraction method. (WJL-608 laser particle size analyzer) no further processes were done after mixing.

Experimental Part Direct compression of the powder blends. Evaluation of the tablets: - Weight Variation . - Hardness and Friability . - Content Uniformity . - Wetting time (paper and petri dish method) - In vitro disintegration time (petridish and disintegrator methods). * Dissolution test (USP NF 2013, type I apparatus)

Scaling up Three batches were prepared to evaluate feasibility and coast effectiveness of the work. They were prepared in Pharmaceuticals. 5 kg batch 20 kg batch 50 kg batch. The tablets resulted from 50 kg were also evaluated for the same parameters.

Results and Discussion Evaluation of the powder blend. 1- Particle size distribution : results showed superior PSD of the ready made blend. The average PS was smaller and showed higher uniformity foe F6 with the co-processed excipient.

Powder characteristics Table (2) Results of powder Evaluation Formula code F1 F2 F3 F4 F5 F6 Bulk Density (g/ml) 0.48 0.47 0.49 0.58 0.51 Tapped Density (g/ml) 0.55 0.54 0.56 0.66 Angle of Repose (degree) 28o 27o 30o 32o 31o 23o Percentage comprissibility 12.72 12.69 10.90 14.2 12.12 8.93 Hausner ratio 1.14 1.15 1.12 1.16 1.13 1.09

Table (3) Results of Evaluation of Tablets Formula code Weight variation Hardness kg/cm2 Friability (%) Wetting time (sec) In vitro DT (sec) Drug Content (%) F1 Pass 3.5±0.51 0.61±0.05 38±1.1 40±1.3 98±1.5 F2 3.6±0.62 0.60±0.06 48±1.5 45±2.1 99±2.0 F3 3.4±0.38 0.63±0.09 45±2.0 48±2.0 100±1.1 F4 3.5±0.44 0.55±0.09 29±1.8 32±1.2 101±0.98 F5 3.7±0.51 0.52±0.08 35±2.1 36±3.1 98±0.99 F6 3.2±0.08 0.40±0.01 30±1.5 31±1.3 99±0.5

Fig 1: Dissolution Profile of the six prepared formulas Drug Dissolution Fig 1: Dissolution Profile of the six prepared formulas

Dissolution of Drug Formula Code F1 F2 F3 F4 F5 F6 Percent drug dissolved T (5 min) 25±2.0 24±1.8 24±1.2 28±1.9 22±2.0 50±1.8 Higher dissolution rate was achieved in the first five minutes with F6 All evaluation results above were obtained from the 50-kg batch

Coast effect and advantages Preliminary Evaluation of coast: Time saving: average 3 hours/working day. Mixing time of F6 is about 1/3 of that of other formulas. Preparation and weighing average of 2 hr saving. Labour : 2 workers less for the major processes. Energy saving: around 3 hours working/batch. Materials coast: 30% less.

Conclusion Using ready-made excipients in formulation of levofloxacin ODT added an advantage over the physical mixture of excipients in characteristics of the result tablets and cost effect.

Acknowledgment All thanks to my University (Al-Ahliyya Amman University) for support of scientific research. And to the cooperating Pharmaceuticals in Jordan for their highly appreciated help in this work. Thanks are extended to my colleagues and students who inspire me all the time.

Thank you For your kind Attention! You are welcome in Jordan